Dyne Therapeutics, Inc. — 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual report; the supplied filing does not provide standalone fourth-quarter results. Dyne is a clinical-stage biotechnology company developing muscle-disease therapies using its FORCE platform. It had no approved products and generated no revenue.
Financial performance and position
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $142.8 million | $121.3 million |
| General and administrative expense | $28.2 million | $28.7 million |
| Total operating expenses / operating loss | $171.0 million | $150.0 million |
| Net loss | $168.1 million | $149.3 million |
| Basic and diluted loss per share | $3.23 | $2.93 |
| Net cash used in operating activities | $153.6 million | $119.6 million |
Net loss increased by $18.8 million, or approximately 12.6%. Total operating expenses rose by $20.9 million, mainly reflecting higher R&D spending; R&D expense increased $21.5 million as the company prepared and began its clinical trials. G&A expense was broadly flat. Revenue-based margins are not meaningful because Dyne had no revenue.
- Liquidity: At year-end, cash and cash equivalents were $172.1 million and marketable securities were $83.9 million, totaling approximately $256.0 million. Current assets were $265.6 million and current liabilities were $28.1 million.
- Cash flows: Investing activities provided $87.2 million, largely from maturities of marketable securities; financing activities provided $37.4 million, primarily from at-the-market (ATM) stock sales. Cash, cash equivalents and restricted cash decreased $29.1 million.
- Debt and obligations: The filing reports no borrowings in the presented balance sheet. Lease liabilities totaled $30.5 million, including $4.6 million current and $25.9 million noncurrent.
- Equity financing: The company sold 3.43 million shares through its ATM program in 2022 for net proceeds of $36.9 million, at a weighted-average price of $11.11 per share. Shares outstanding were 55.64 million at year-end and 56.34 million as of February 28, 2023.
Programs, changes and outlook
- DYNE-101 for DM1: Enrollment began in the global Phase 1/2 ACHIEVE trial in September 2022. The company expected initial safety, tolerability and splicing data from the multiple-ascending-dose portion in the second half of 2023.
- DYNE-251 for DMD: Enrollment began in the global Phase 1/2 DELIVER trial in August 2022. The FDA cleared the IND in July 2022 after placing it on clinical hold in January and requesting additional clinical and nonclinical information. The FDA granted Fast Track designation in October 2022. Initial safety, tolerability and dystrophin data were expected in the second half of 2023.
- DYNE-301 for FSHD: In September 2022, Dyne deferred the planned IND submission, originally targeted for the second half of 2022, to prioritize resources for DYNE-101 and DYNE-251. It planned to update investors on the program by the end of 2023.
- Cash runway: Management said year-end cash, cash equivalents and marketable securities were expected to fund operations and capital needs through 2024 and support anticipated proof-of-concept readouts for DYNE-101 and DYNE-251. This is an estimate based on assumptions and may change.
- Development stage: Both lead programs were in early clinical development; the company had not completed a clinical trial of any product candidate. Preclinical findings described in the filing are not evidence of clinical benefit in people.
Risks, contingencies and other notable items
- Dyne expects substantial ongoing losses and says it will need additional financing. It has no committed source of additional capital; future equity financing could dilute shareholders, while debt or partnerships could impose restrictions or require rights to be relinquished.
- Clinical and regulatory success is uncertain. Key risks include safety or efficacy failures, trial delays or enrollment challenges, and the possibility that preclinical results will not predict human outcomes.
- Dyne relies on third parties for research, clinical testing and manufacturing. The filing highlights dependence on a small number of suppliers, including single suppliers for its Fab, linker and payload components, and the lack of redundant supply arrangements for all materials.
- Competition, intellectual-property challenges, reimbursement and pricing uncertainty, and evolving privacy, healthcare and regulatory requirements could affect development and any future commercialization.
- There were no material legal proceedings. The independent auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2022; the auditor did not attest to internal-control effectiveness because of the company’s emerging-growth-company exemption.
- Research and development accruals and stock-based compensation are identified as critical accounting estimates. Management reported no material differences to date between estimated and actual accrued R&D costs.
Important facts for investors to verify
- Whether actual cash use and updated forecasts support the stated runway through 2024, including the assumptions behind expected trial readouts.
- Clinical-trial status, safety, tolerability and efficacy data for DYNE-101 and DYNE-251, and whether trial timelines or designs have changed.
- Any subsequent changes to the deferred DYNE-301 program and resource allocation among pipeline programs.
- Additional financing needs, ATM usage, share-count changes and resulting dilution.
- Manufacturing capacity, supplier concentration and progress toward qualified backup sources for critical components.
- Potential limitations on use of tax attributes: the company reported $221.1 million of federal and $221.9 million of state net operating loss carryforwards, with some carryforwards subject to ownership-change limitations.